Dr. Divita Mathur’s team at Case Western Reserve University has pioneered synthetic DNA nanoparticles facilitating efficient intracellular delivery and gene editing, supported by a National Science Foundation CAREER grant. These nanoparticles improve stability and targeting of nucleic acid therapeutics, expediting drug development. Utilization of protein barcoding coupled with next-gen protein sequencing accelerates mRNA therapeutic screening, enabling scalable evaluation of delivery and expression across formulations, moving gene therapies toward broader clinical applications.